RESEARCH ARTICLE

RNA sequencing to determine the contribution of kinase receptor transactivation to G protein coupled receptor signalling in vascular smooth muscle cells

Danielle Kamato 1 *, Venkata Vijayanand Bhaskarala 2, Nitin Mantri 2, Tae Gyu Oh 3, Dora Ling 1, Reearna Janke 1, Wenhua Zheng 4, Peter J Little 1,5, Narin Osman 1,6,7

1 School of Pharmacy, The University of Queensland, Pharmacy Australia Centre of Excellence, Woolloongabba, QLD, Australia, 2 Department of Biotechnology and Environmental Biology, School of Applied Sciences, RMIT University, Bundoora, VIC, Australia, 3 Institute for Molecular Bioscience, The University of Queensland, St Lucia, Qld, Australia, 4 Faculty of Health Sciences, University of Macau, Taipa, China, 5 Xinhua College of Sun Yat-sen University, Tianhe District, Guangzhou, China, 6 Diabetes Complications Group, School of Health and Biomedical Sciences, RMIT University, Bundoora, VIC, Australia, 7 Monash University, Departments of Medicine and Immunology, Central and Eastern Clinical School, Alfred Health, Melbourne, VIC, Australia

* d.kamato@uq.edu.au

Abstract

G protein coupled receptor (GPCR) signalling covers three major mechanisms. GPCR agonist engagement allows for the G proteins to bind to the receptor leading to a classical downstream signalling cascade. The second mechanism is via the utilization of the β-arrestin signalling molecule and thirdly via transactivation dependent signalling. GPCRs can transactivate protein tyrosine kinase receptors (PTKR) to activate respective downstream signalling intermediates. In the past decade GPCR transactivation dependent signalling was expanded to show transactivation of serine/threonine kinase receptors (S/TKR). Kinase receptor transactivation enormously broadens the GPCR signalling paradigm. This work utilizes next generation RNA-sequencing to study the contribution of transactivation dependent signalling to total protease activated receptor (PAR)-1 signalling. Transactivation, assessed as gene expression, accounted for 50 percent of the total genes regulated by thrombin acting through PAR-1 in human coronary artery smooth muscle cells. GPCR transactivation of PTKRs is approximately equally important as the transactivation of the S/TKR with 209 and 177 genes regulated respectively, via either signalling pathway. This work shows that genome wide studies can provide powerful insights into GPCR mediated signalling pathways.

Introduction

G protein coupled receptors (GPCRs) are the most prolific and polyfunctional receptors in biology [1, 2]. GPCRs control diverse physiological functions which include, relaxation of blood vessels, acceleration of heart rate, transmission of sight impulses, biorhythms and...
olfaction [3]. Drugs targeting GPCRs are the largest class of therapeutic agents for diseases including but not limited to: cardiovascular disease, cancer, hypertension and asthma [4–8]. The current paradigm of GPCR signalling covers three major pathways: firstly the well-defined classic signalling pathway which agonist engagement causes G protein binding to the receptor with subsequent downstream signalling leading to functional responses [9–11]. Secondly, the β-arrestin scaffold pathway which leads to the activation of multiple downstream signalling cascades [12]. Two decades ago, the GPCR signalling pathways were complemented by the finding that GPCRs could activate protein tyrosine kinase receptors (PTKRs) leading to the activation of the downstream signalling pathways [13]. This pathway termed transactivation, is the third major signalling pathway of GPCR which was recently expanded to include GPCR mediated transactivation of serine/threonine kinase receptors (S/TKR) [14–18].

The activation of PTKRs by a GPCR immensely expands the range of cellular functions attributable to GPCRs [13, 19, 20]. An example from the vascular biology field is the acute activation of an Angiotensin II receptor in a transactivation independent response leads to a very rapid mobilization of intracellular calcium ions and vascular contraction [21] whereas transactivation of PTKRs leads to a slow vascular remodelling due to cell proliferation and extracellular matrix synthesis [22]. Angiotensin II transactivation goes beyond the vasculature, this signalling pathway has also been shown to be important in kidney [23], heart [24, 25] and cancer [26]. The paradigm of GPCR transactivation signalling has expanded to include the transactivation of the S/TKR and notably the transforming growth factor (TGF)-β receptor (TGFBR1). The phenomenon of transactivation dependent signalling of the PTKR family includes receptors for epidermal growth factor (EGF), platelet derived growth factor, insulin-like growth factor-1 and fibroblast growth factor [13, 27–29]. However GPCR dependent transactivation of the S/TKR is currently restricted to the TGF-β receptor superfamily [15–18, 30–32].

In human vascular smooth muscle cells (VSMCs) the mechanisms involved in PAR-1 mediated transactivation of the PTKR, EGFR, and the S/TKR, TGFBR1, have been partially defined. PAR-1 transactivation of the EGFR involves the activation of cell surface matrix metalloproteases that cleave and release membrane anchored EGFR ligands. PAR-1 transactivation of the TGFBR1 is mediated by cytoskeletal rearrangement which activates ROCK signalling, leading to the activation of cell surface integrins, which bind to the latent TGF-β complex. This allows for the TGF-β ligand to bind to its receptor. These two transactivation dependent pathways are fully functional in the context that they lead to glycosaminoglycan (GAG) enzyme expression [33] and GAG chain elongation [15]. Beyond this model of proteoglycan synthesis in VSMCs the important transactivation signalling to GPCR signalling is unknown.

To recognize the extent of transactivation dependent signalling a genome-wide study can help identify some promising candidates of PAR-1 transactivation of the TGFBR1 or EGFR. Whole genome RNA sequencing allows for the comprehensive study of the mRNAs in the sample. This new platform has produced high throughput sequencing in the study of various diseases [34–38]. Hannan [39] adapted a similar approach to identify the underlying biology in transactivation of the EGFR. Using a functional siRNA screen of the human genome, the role of 720 kinases was investigated in Angiotensin II mediated transactivation of the EGFR [39]. However in the present study, RNA sequencing analysis was employed to provide an approach to examine the changes induced by PAR-1 transactivation dependent signalling in global gene expression in human coronary artery smooth muscle cells (CASMCs).

**Materials and methods**

RNase-Free DNase set and miRNeasy kit were purchased from Qiagen. Dynabeads® mRNA DIRECT™ Micro kit, Ion PI™ Template OT2 Supplies 200 kit v2, Ion PI™ Template OT2
Reagents 200 Kit v2, Ion PI™ Template OT2 Solutions 200 kit v2, Ion PI™ Sequencing Supplies 200, Ion PI™ Sequencing reagents 200, Ion PI™ Sequencing solutions 200 v2, Ion PI™ Chip preparation solution and Ion Proton™ Chip Adapter where purchased from Life Technologies.

Cell culture

Human CASMCS (purchased from Lonza Cat No. CC-2583, Lot No. 0000317155) were grown in DMEM (5mM glucose, 10% FBS and 1% antibiotics at 37˚C in 5% CO₂) and were seeded in 60 mm dishes. Cells were grown to confluence then rendered quiescent by serum deprivation for 48 hours. Inhibitors to TGFBR1 (SB431542 10μM) and EGFR (AG1478 5μM) were pre-incubated for 30 mins prior to treatment with thrombin (10 units/ml) for 6 hours. RNA extraction and library preparation followed the manufacturer’s instructions.

Quality control and read alignment

QuadTrim was used for quality trimming of RNA-sequencing reads. Raw reads with Q-score greater than 20 (>Q20) were retained for further analysis. High quality filtered reads were aligned to the human reference genome (hg19) using Bowtie v2.2.4 and TopHat v2.1.1 [40, 41]. Uniquely mapped reads were then used for counting reads using HTSeq [42].

Differential gene expression and functional analysis

The genes differentially expressed between the different treatments were identified using edgeR v3.0.7 [43], a Bioconductor package of R statistical environment [44]. This method uses a Poisson distribution to model genic read counts following normalization based on size factors and variance, therefore this software allows normalization of RNA-sequence data based on sequencing depth GC content and gene length for analysis of differentially expressed genes. Differentially expressed genes were defined with log2FC of >0.7 or <−0.7 significant at p value <0.01 (FDR 0.05). STRING (v10.0) (http://string-db.org), a publically available online database of functional interaction [45] was used to identify gene ontology analysis and networks, the differentially expressed genes were analysed. The Venn diagrams were depicted using JVENN an interactive tool to view Venn diagrams and respective lists [46].

Western blotting

Total cell lysates were resolved on 10% SDS-PAGE and transferred onto PVDF. Membranes were blocked with 5% bovine serum albumin, incubated with ANKRD1 polyclonal antibody (ab88456) and followed by HRP anti-rabbit IgG and ECL detection.

Assessing mRNA gene expression

The mRNA level of ANKRD1 was determined by real-time polymerase chain reaction (RT-PCR). Total RNA was isolated from treated CASMCS using RNeasy Mini kit (Qiagen) according to the manufactures’ instructions. First strand cDNA was synthesized from 1μg RNA using Quantitect reverse transcriptase kit (Qiagen). Quantitative RT-PCR was performed using Qiagen Rotor Gene Q and QuantiNova SYBR Green PCR Master Mix kit (Qiagen). RT-PCR used human specific ANKRD1 primer sequences. The data was normalized to 8S as the house keeping gene. Relative expression of mRNA levels was quantified using comparative delta delta Ct method.
Results and discussion

Gene expression profiles of the treatments

A genome wide RNA-Seq sequencing study was conducted to determine the portion of GPCR signalling which is occurring via transactivation dependent signalling in human CASMCs (Fig 1). The individual treatment groups (Basal, Thrombin, Thrombin+AG1478, Thrombin+SB431542 or Thrombin+AG1478+SB431542) contained 2–4 individual samples pooled together for each of the groups to identify the differentially expressed genes. A total of 3 pooled samples from RNA isolated from untreated CASMCs (Fig 1A), averaged 8 million reads and 82.7% of the total reads were mapped to the human reference genome (hg19). The RNA was harvested from human CASMCs treated with thrombin for 6 hours (Fig 1B), consisted of 4 pooled samples with an average of 12 million reads. This relatively short stimulation period was chosen to focus on primary signalling from GPCR to gene expression, to the exclusion of later responses which may be secondary and beyond responses to the expression of intermediate genes. Among the total number of reads 83.3% of the reads were mapped to the human reference genome (hg19). The differentially expressed genes regulated via PAR-1 mediated transactivation of the EGFR were obtained when CASMCs were treated with thrombin in the presence of EGFR antagonist, AG1478. For

![Fig 1. Summary of RNA-sequencing data.](https://doi.org/10.1371/journal.pone.0180842.g001)

The table and the pie charts represent the average mapping statistics for each of the individual treatments using TopHat. RNA extraction from human CASMCs A Untreated B treated with thrombin for 6 hours C treated with thrombin in the presence of AG1478 (5μM) D treated with thrombin in the presence of SB431542 (10μM) E treated with thrombin in the presence of both AG1478 and SB431542.

https://doi.org/10.1371/journal.pone.0180842.g001
this treatment, there was a total of 2 pooled samples (Fig 1C) with an average of 13.5 million reads, 82.3% of these reads were mapped to the human reference genome (hg19). To determine the number of differentially expressed genes occurring via the transactivation of the TGFBR1, CASMCs were treated with thrombin in the presence of TGFBR1 antagonist, SB431542. For this treatment group there was a total of 4 samples pooled together (Fig 1D) with an average read of 13.1 million reads. Among the total number of reads 81.2% of the reads were mapped to the human reference genome (hg19). The treatment showing the genes regulated via dual transactivation dependent signalling pathways were treated with thrombin in the presence of EGFR and TGFBR1 antagonists AG1478 and SB431542, respectively (Fig 1E). A total of 3 individual samples were pooled to give an average of 10.9 million reads. Among the total reads 82.2% of the reads were aligned to the human genome (hg19).

The small sample size in our RNA-Seq study is consistent with other RNA-Seq sequencing studies published which are based on sample sizes of equal to or less than 3 [35]. In human samples greater than 80% of the read pairs can be expected to be mapped to the reference genome [47]. Consistent with the literature [48] the output from our RNA-Seq study shows that over 80% of the reads are mapped to the human genome. This analysis validates that the RNA used to identify the differentially expressed genes are of high quality.

**GPCR mediated transactivation of PTKR and S/TKR accounts for over half of GPCR mediated signalling**

To assess the contribution of transactivation dependent signalling to overall GPCR signalling, RNA sequencing was conducted. To study the role of PTKR, the EGFR antagonist, AG1478, was used and to study S/TKR transactivation the TGFBR1 antagonist, SB431542, was utilized. We have previously reported that at the concentrations used there is no cross over of inhibitory activity from either drug to either of the target samples [49]. In the present study the differential expression analysis was carried out using a multiple comparison software analysis, edgeR. Each of the treated samples was initially compared to the basal sample. The samples treated with thrombin in the presence of the receptor antagonists were further compared to the CASMCs treated with thrombin alone. The results from this multiple comparison are presented in Fig 2.

Thrombin treatment of human CASMCs resulted in 293 differentially expressed genes increasing in expression as compared to basal. A total of 209 genes were differentially regulated when CASMCs were treated with thrombin in the presence of AG1478. In the presence of AG1478, 80 of the 209 differentially expressed genes had an increase in expression as compared to thrombin treatment alone. The remaining 129 genes differentially regulated by AG1478 had a decrease in expression as compared to thrombin treatment alone (Fig 2). A total of 177 genes are differentially expressed when CASMCs are treated with thrombin in the presence of SB431542. The expression of 26 genes increase in the presence of SB431542 as compared to thrombin treatment alone and 151 genes have a decrease in expression in the presence of the antagonist as compared to thrombin treatment alone (Fig 2). When the two antagonists were combined, a total of 212 genes were differentially expressed, the expression of 166 genes was decreased in the presence of dual antagonists as compared to thrombin and the expression of 46 genes were increased as compared to thrombin treatment alone (Fig 2). Thus these results show that transactivation dependent signalling plays an important role in GPCR signalling with 209 genes regulated via the transactivation of the EGFR, 177 genes regulated via thrombin transactivation of the TGFBR1 and 212 genes regulated via dual transactivation of the EGFR and TGFBR1.
Over the past two decades there have been studies expanding on GPCR mediated transactivation signalling of PTKR specifically the EGFR [39, 50, 51]. GPCR mediated transactivation dependent signalling also spans out to include activation of the TGFBR1. Although this latter pathway was first identified a decade ago [17], there has been a limited amount of studies investigating this transactivation pathway as compared to investigations into the transactivation of the EGFR. Interestingly, the results of this RNA sequencing data show that transactivation dependent signalling via the TGFBR1 is equally as important as transactivation of the EGFR as there is a large number of genes regulated when CASMCs are treated with the respective receptor antagonists in the presence of thrombin.

Of the total number of genes differentially regulated by the individual treatments, a Venn diagram was composed to show commonly regulated genes between the individual transactivation dependent pathways (Fig 3). Of the 209 genes differentially expressed by thrombin transactivation of the EGFR, there were 14 genes common to transactivation of TGFBR1 and 19 genes were found to be common in thrombin transactivation of the EGFR and in transactivation of both EGFR and TGFBR1. The genes differentially expressed by thrombin transactivation of the EGFR have 50 genes, which are not common with either of the other two treatments (Fig 3).
Thrombin transactivation of the TGFBR1 results in 177 differentially expressed genes, 20 of these genes are in common with thrombin transactivation of both the EGFR and TGFBR1, and 17 genes are specific to transactivation of the TGFBR1. The three individual lists of differentially expressed genes from each of the transactivation pathways share 126 genes which are common. This shows that over 60% of the differentially expressed genes are common between the transactivation dependent signalling pathways. These results indicate that although these two transactivation dependent pathways are independent of each other and their biochemical pathways are

Fig 3. Depicted is the Venn diagram showing the differentially expressed genes of each of the treatments. Thrombin transactivation of the EGFR (209 genes), thrombin transactivation of the TGFBR1 (177 genes) and thrombin transactivation of both EGFR and TGFBR1 (212 genes).

https://doi.org/10.1371/journal.pone.0180842.g003
mechanistically distinct, they regulate over 60% of the same genes which may indicate that they may be involved in regulating common biological processes.

There are a number of common downstream signalling intermediates which are common to both EGFR and TGFBR1 signalling. MAPKs such as Erk, p38 and Jnk are amongst the common signalling intermediates between the two pathways. MAPKs play a role in transmitting extracellular signals from cell surface receptors to intracellular target and are activated by both TGF-β [52–55] and EGF [56–58]. Similarly other serine/threonine kinases such as PI3K and glycogen synthase kinase 3 are common downstream intermediates to both these signalling pathways [57, 59–63]. Thus common downstream signalling intermediates may allow for convergence; allowing for over 60% of differentially expressed genes to be common between the two pathways.

The differential expression data was divided into the up and down regulated genes of each of the transactivation pathways. The Venn diagram in Fig 4 illustrates that from the 80 genes

![Venn diagram](https://doi.org/10.1371/journal.pone.0180842.g004)

**Fig 4.** Depicted is the Venn diagram showing the genes up and down regulated by each of the transactivation dependent signalling pathways. 209 genes are differentially expressed via thrombin transactivation of the EGFR (80 upregulated and 129 down regulated) and 177 genes are differentially expressed via thrombin transactivation of the TGFBR1 (26 upregulated and 141 down regulated).
up regulated in thrombin transactivation of EGFR, 19 genes are also commonly up regulated in thrombin transactivation of the TGFBR1. There are 129 genes that are down regulated via thrombin transactivation of the EGFR and of this gene list 108 are commonly down regulated in thrombin mediated transactivation of the TGFBR1. Interestingly there are 13 genes which are up regulated in thrombin transactivation of the EGFR and down regulated in transactivation of the TGFBR1 (Fig 4). These results show that over 80% of the genes down regulated by either pathway are common with only 33% of EGFR mediated transactivation dependent signalling to be specific to EGFR and 20% of genes specific to TGFBR1 transactivation.

Genes most up and down regulated by the individual transactivation dependent pathways

Overall, there were 209 genes differentially regulated by thrombin transactivation of the EGFR (Fig 2). The top 10 up regulated genes are involved in molecular functions such as cytokine activity which controls cell growth, survival and differentiation as well as genes which are involved in transcription factor activity (Table 1). The top most down regulated genes via EGFR transactivation are involved in receptor protein activity and protein kinase binding (Table 1).

There were a total of 177 genes regulated by thrombin transactivation of the TGFBR1 (Table 2). The top 10 most upregulated genes include genes which were associated with GTP-binding including TUBB2A, TUBB4B and TUBA1C (Table 2). Also included in the top most up regulated genes by thrombin transactivation of the TGFBR1 were genes associated with phospholipid binding and phosphatase activity. The majority of the genes down regulated by

Table 1. Genes most up regulated and down regulated by thrombin transactivation of the EGFR in vascular smooth muscle cells.

| Gene ID               | Gene               | Gene Title                                      | Thr  | Thr+AG |
|----------------------|--------------------|-------------------------------------------------|------|--------|
| ENSG00000123358      | NR4A1              | Nuclear receptor subfamily 4 group A member 1   | 14.02| 19.63  |
| ENSG00000100311      | PDGFB              | Platelet-Derived Growth Factor Beta Polypeptide | 6.74 | 7.05   |
| ENSG00000109321      | AREG               | Amphiregulin                                    | 6.87 | 6.92   |
| ENSG00000115009      | CCL20              | Chemokine (C-C Motif) Ligand 20                 | 4.67 | 6.42   |
| ENSG00000197632      | SERPINB2           | Serpin Peptidase Inhibitor, Clade B (Ovalbumin), Member 2 | 1.34 | 5.01   |
| ENSG00000136244      | IL6                | Interleukin 6                                   | 3.82 | 4.63   |
| ENSG00000154319      | FAM167A            | Family With Sequence Similarity 167, Member A   | 3.08 | 4.38   |
| ENSG00000120738      | EGR1               | Early Growth Response 1                         | 1.39 | 4.30   |
| ENSG00000117525      | F3                 | Coagulation Factor III (Thromboplastin, Tissue Factor) | 2.27 | 3.83   |
| ENSG00000168389      | MFSD2A             | Major Facilitator Superfamily Domain Containing 2A | 1.41 | 3.59   |

Most down regulated

| Gene ID               | Gene               | Gene Title                                      | Thr  | Thr+AG |
|----------------------|--------------------|-------------------------------------------------|------|--------|
| ENSG00000127951      | FGL2               | Fibrinogen-Like 2                               | 16.22| 3.12   |
| ENSG00000153234      | NR4A2              | Nuclear receptor subfamily 4 group A member 2   | 9.09 | 8.15   |
| ENSG00000102760      | RGCC               | Regulator Of Cell Cycle                         | 8.99 | 4.09   |
| ENSG00000119508      | NR4A3              | Nuclear receptor subfamily 4 group A member 3   | 8.11 | 4.92   |
| ENSG00000095752      | IL11               | Interleukin 11                                  | 6.14 | 3.03   |
| ENSG00000144063      | MALL               | Mal, T-Cell Differentiation Protein-Like        | 5.81 | 1.16   |
| ENSG00000162494      | LRRCC38            | Leucine Rich Repeat Containing 38               | 5.48 | 3.87   |
| ENSG00000078401      | EDN1               | Endothelin 1                                    | 5.17 | 1.02   |
| ENSG00000111859      | NEDD9              | Neural Precursor Cell Expressed, Developmentally Down-Regulated 9 | 4.92 | 2.06   |
| ENSG00000106278      | PTPRZ1             | Protein Tyrosine Phosphatase, Receptor-Type, Z Polypeptide 1 | 4.57 | 1.03   |

https://doi.org/10.1371/journal.pone.0180842.t001
this transactivation dependent pathway include genes which were associated with transcription factor activity (Table 2).

Treatment with the two receptor antagonists to assess the contribution of all the transactivation dependent signalling showed 212 genes differentially expressed. The top 10 most upregulated genes of this transactivation pathway were associated with transcription factor activity, cytokine activity and receptor binding activity (Table 3). From the list of differentially expressed genes occurring via the transactivation of both receptors the most downregulated genes are associated with receptor protein and cytokine activity.

Interestingly many of the top 10 up and down regulated genes are common between the three treatments. Amongst the top 10 most up regulated genes in thrombin transactivation of the EGFR (Table 1) and via dual transactivation dependent pathways are NR4A1, CCL20 and IL6 (Table 3). These genes are involved in regulating transcription factor, cytokine and growth factor activity. The SERPINB2 and the EGR1 are common in the top up regulated genes in thrombin transactivation of EGFR (Table 1) and TGFBR1 (Table 2). Interestingly although these two genes are in the top upregulated genes of each of the transactivation dependent pathways when the two receptor antagonists were used together these genes did not appear to be in the top 10 most upregulated genes.

In the top most down regulated genes of each of the treatments there were more than 70% commonly expressed genes. The top 10 most down regulated genes dependent on transactivation of the EGFR, TGFBR1 or both pathways have FGL2, PGCC, IL11, MALL, LRRc38 and EDN1 common between the three conditions (Tables 1–3). These genes are commonly associated with cytokine activity and receptor binding. The NR4A2 and NR4A3 genes are common

### Table 2. Genes most up regulated and down regulated by thrombin transactivation of the TGFBR1 in vascular smooth muscle cells.

| Gene ID               | Gene          | Gene Title                                      | Thr   | Thr+SB |
|-----------------------|---------------|-------------------------------------------------|-------|--------|
| ENSG00000171246       | NPTX1         | Neuronal Pentraxin I                            | 1.62  | 6.26   |
| ENSG00000197632       | SERPINB2      | Serpin Peptidase Inhibitor, Clade B (Ovalbumin), Member 2 | 1.34  | 4.68   |
| ENSG00000120738       | EGR1          | Early Growth Response 1                         | 1.39  | 4.55   |
| ENSG00000168389       | MFSD2A        | Major Facilitator Superfamily Domain Containing 2A | 1.41  | 3.28   |
| ENSG00000137267       | TUBB2A        | Tubulin, Beta 2A Class Iia                      | 2.38  | 3.16   |
| ENSG00000138166       | DUSP5         | Dual Specificity Phosphatase 5                  | 1.46  | 3.12   |
| ENSG00000188229       | TUBB4B        | Tubulin, Beta 4B Class Ivb                      | 1.67  | 2.90   |
| ENSG00000167553       | TUBA1C        | Tubulin, Alpha 1c                               | 1.99  | 2.85   |
| ENSG00000173641       | HSPB7         | Heat Shock 27kDa Protein Family, Member 7 (Cardiovascular) | 1.45  | 2.66   |
| ENSG00000128228       | SDF2L1        | Stromal Cell-Derived Factor 2-Like 1            | 1.41  | 2.61   |

| Gene ID               | Gene          | Gene Title                                      | Thr   | Thr+SB |
|-----------------------|---------------|-------------------------------------------------|-------|--------|
| ENSG00000127951       | FGL2          | Fibrinogen-Like 2                               | 16.26 | 4.43   |
| ENSG00000123358       | NR4A1         | Nuclear receptor subfamily 4 group A member 1   | 14.07 | 10.21  |
| ENSG00000153234       | NR4A2         | Nuclear receptor subfamily 4 group A member 2   | 9.11  | 3.93   |
| ENSG00000102760       | RGCC          | Regulator Of Cell Cycle                         | 9.00  | 2.59   |
| ENSG00000119508       | NR4A3         | Nuclear receptor subfamily 4 group A member 3   | 8.12  | 3.24   |
| ENSG00000100311       | PDGFB         | Platelet-Derived Growth Factor Beta Polypeptide | 6.76  | 1.31   |
| ENSG00000095752       | IL11          | Interleukin 11                                  | 6.16  | 0.84   |
| ENSG00000144063       | MALL          | Mal, T-Cell Differentiation Protein-Like        | 5.81  | 1.84   |
| ENSG00000162494       | LRRc38        | Leucine Rich Repeat Containing 38               | 5.50  | 2.46   |
| ENSG00000078401       | EDN1          | Endothelin 1                                    | 5.18  | 0.46   |

https://doi.org/10.1371/journal.pone.0180842.t002
in the top 10 most down regulated genes in thrombin transactivation of TGFBR1 (Table 2) and transactivation of the EGFR (Table 1), interestingly when the two receptor antagonists were applied together (Table 3) these two genes are amongst the top most up regulated genes. The NR4A1 gene found in the most up regulated genes in thrombin transactivation of the EGFR (Table 1) and dual transactivation (Table 3) is amongst the top most down regulated gene via thrombin transactivation of the TGFBR1 (Table 1). Similarly, the PDGFB and the AREG genes associated with protein heterodimerization and EGFR binding, respectively were found in the top 10 most down regulated genes in the dual transactivation dependent signal-ling (Table 3) and in the top 10 most up regulated genes in thrombin transactivation of the EGFR alone (Table 1). These results show that while genes may be up/down regulated when the dual transactivation pathways are activated, the genes may act opposing in the presence of a single receptor antagonist thus showing the complex nature of transactivation dependent signalling.

In ovarian cancer cells the ET-1 receptor transactivates the EGFR [64, 65] and the vascular endothelial growth factor receptor [66] leading to the expression of EDN1. The expression of EDN1 has also been shown to be involved in colon and prostate cancer cell lines [67, 68]. EDN1 is one of the most down regulated genes in thrombin mediated transactivation of the TGFBR1 (Table 2) and is highly down regulated in the presence of receptor antagonists to both transactivation receptor pathways (Table 3). The role of EDN1 in GPCR mediated transactivation of S/TKR is unknown however EDN1 has a binding site for TGF-β activated Smad transcription factor [69]. In palate development TGF-β treatment increased the expression of EDN1 [70], thus consistent with our results which show that thrombin can transactivate the

### Table 3. Genes most up regulated and down regulated by thrombin transactivation of the TGFBR1 and EGFR in vascular smooth muscle cells.

| Gene ID       | Gene          | Gene Title                                      | Thr  | Thr+AG+SB |
|---------------|---------------|-------------------------------------------------|------|-----------|
| Most Up regulated |               |                                                 |      |           |
| ENSG00000123358 | NR4A1         | Nuclear receptor subfamily 4 group A member 1  | 14.05| 16.91     |
| ENSG00000153234 | NR4A2         | Nuclear receptor subfamily 4 group A member 2  | 9.10 | 20.95     |
| ENSG00000119508 | NR4A3         | Nuclear receptor subfamily 4 group A member 3  | 8.12 | 7.14      |
| ENSG00000115009 | CCL20         | Chemokine (C-C Motif) Ligand 20                | 4.69 | 6.88      |
| ENSG00000136244 | IL6           | Interleukin 6                                  | 3.83 | 4.50      |
| ENSG00000073756 | PTGS2         | Prostaglandin-Endoperoxide Synthase 2           | 3.33 | 3.81      |
| ENSG00000146374 | RSPO3         | R-Spondin 3                                    | 2.50 | 2.74      |
| ENSG00000115008 | IL1A          | Interleukin 1, Alpha                           | 2.45 | 2.73      |
| ENSG00000143878 | RHOB          | Ras Homolog Family Member B                    | 2.42 | 2.70      |
| ENSG00000088826 | SMOX          | Spermine Oxidase                               | 2.14 | 2.21      |
| Most down regulated |               |                                                 |      |           |
| ENSG00000127951 | FGL2          | Fibrinogen-Like 2                              | 16.26| 4.14      |
| ENSG000000102760 | RGCC          | Regulator Of Cell Cycle                        | 9.00 | 3.48      |
| ENSG00000109321 | AREG          | Amphireguin                                    | 6.89 | 3.93      |
| ENSG00000100311 | PDGFB         | Platelet-Derived Growth Factor Beta Polypeptide| 6.75 | 2.82      |
| ENSG00000095752 | IL11          | Interleukin 11                                 | 6.16 | 1.51      |
| ENSG00000144063 | MALL          | Mal, T-Cell Differentiation Protein-Like       | 5.81 | 1.65      |
| ENSG00000162494 | LRRC38        | Leucine Rich Repeat Containing 38              | 5.51 | 1.56      |
| ENSG00000078401 | EDN1          | Endothelin 1                                   | 5.19 | 0.55      |
| ENSG000001111859 | NEDD9         | Neural Precursor Cell Expressed, Developmentally Down-Regulated 9 | 4.93 | 1.61      |
| ENSG00000106278 | PTPRZ1        | Protein Tyrosine Phosphatase, Receptor-Type, Z Polypeptide 1 | 4.59 | 1.23      |

https://doi.org/10.1371/journal.pone.0180842.t003
TGFBR1 which is involved in the regulation of EDN1. Thus showing that thrombin transactivation of the TGFBR1 and EGFR has the potential to be involved in growth related diseases such as cancer and palate development.

**Biological processes regulated by the transactivation dependent pathways**

In order to examine the biological processes influenced by each of the transactivation pathways, genes differentially expressed by the different treatments were subjected to functional enrichment analysis based on their gene ontology (GO) annotations. From the 209 differentially expressed and regulated genes by thrombin transactivation of the EGFR, there was 512 GO terms with a false discovery rate (FDR) value of less than 0.05. The top 50 biological terms occurring via thrombin transactivation of the EGFR are listed in Table 4. There was a total of 177 genes differentially regulated by thrombin transactivation of the TGFBR1, from this gene list 428 GO terms with an FDR value of less than 0.05. The top 50 biological terms from the 428 genes associated with thrombin transactivation of the TGFBR1 listed in Table 5. Treatment with two receptor antagonists to account for all the transactivation dependent signalling resulted in 212 differentially expressed genes. From this list of genes 440 terms were enriched by dual transactivation dependent signalling. The top 50 GO terms respective to this signalling cascade are listed in Table 6.

From the lists of the top 50 processes most significantly enriched by transactivation dependent signalling, 28 terms were found to be common between the three lists (Tables 4–6). Many of these GO terms are associated with regulation of cell activity as well as terms which are associated with vascular development. This includes development of the cardiovascular system, circulatory system, vasculature and blood vessel. From the list of 50 terms associated with dual transactivation dependent signalling (Table 6), five enriched terms were common to thrombin transactivation of the TGFBR1 (Table 5). The common terms include biological processes which are involved in cell growth, cell death and tissue development. Similarly there were five GO terms which were common to dual transactivation dependent signalling (Table 6) and thrombin transactivation of the EGFR (Table 4). Terms common to these two lists include biological processes associated with the regulation of angiogenesis, vasculature development and blood vessel morphogenesis as well as terms involved in cellular activity. When comparing the terms regulated by transactivation of the TGFBR1 (Table 5) and the EGFR (Table 4) there are 5 GO terms which are common to these two pathways which were not found in the top 50 list of terms via dual transactivation (Table 6). These 5 terms are associated with regulation of metabolic processes and signal transduction. Furthermore, network analysis was conducted using String DB, Figs 5–7 show the networks over represented in the gene list of the respective transactivation dependent pathways.

The results above show that thrombin transactivation of the EGFR, TGFBR1 or both receptors is involved in regulating a large number of biological processes 512, 428 and 440 terms, respectively. With the two transactivation dependent pathways being mechanistically distinct [15], the results of these experiments show that over 55% of the top 50 terms regulated are common between the three treatments. Over 60% of the differentially expressed genes described earlier were common to both thrombin mediated transactivation of the TGFBR1 and transactivation of the EGFR. The common differentially expressed genes resulted in over 55% biological terms, which are common between both transactivation pathways. The commonality between the two individual pathways is due the EGFR pathway sharing common downstream signalling intermediates with the TGFBR1 downstream pathway. Serine/threonine kinases such as MAPKs [52–55] are one of many common downstream intermediates to
Table 4. The top 50 gene ontology terms in the analysis of genes expressed in thrombin transactivation of the EGFR.

| GO ID  | GO Term                                         | Count | FDR   |
|--------|------------------------------------------------|-------|-------|
| GO.0051272 | positive regulation of cellular component movement | 24    | 3.87E-10 |
| GO.0070887 | cellular response to chemical stimulus          | 57    | 4.94E-10 |
| GO.0071310 | cellular response to organic substance          | 51    | 4.94E-10 |
| GO.1901342 | regulation of vasculature development          | 19    | 4.94E-10 |
| GO.2000147 | positive regulation of cell motility            | 23    | 4.94E-10 |
| GO.0051094 | positive regulation of developmental process    | 38    | 1.15E-09 |
| GO.0030335 | positive regulation of cell migration           | 22    | 1.51E-09 |
| GO.0045765 | regulation of angiogenesis                      | 17    | 6.90E-09 |
| GO.2000145 | regulation of cell motility                     | 28    | 7.31E-09 |
| GO.0030334 | regulation of cell migration                    | 27    | 8.80E-09 |
| GO.1904018 | positive regulation of vasculature development  | 14    | 8.80E-09 |
| GO.0009653 | anatomical structure morphogenesis               | 51    | 1.09E-08 |
| GO.0051270 | regulation of cellular component movement       | 29    | 1.32E-08 |
| GO.0051239 | regulation of multicellular organismal process  | 54    | 1.85E-08 |
| GO.0042981 | regulation of apoptotic process                 | 40    | 1.89E-08 |
| GO.0043067 | regulation of programmed cell death             | 40    | 2.16E-08 |
| GO.0001568 | blood vessel development                        | 23    | 2.38E-08 |
| GO.0050793 | regulation of developmental process             | 50    | 2.41E-08 |
| GO.0022603 | regulation of anatomical structure morphogenesis| 31    | 2.59E-08 |
| GO.0042127 | regulation of cell proliferation                | 41    | 2.59E-08 |
| GO.0001944 | vasculature development                        | 23    | 5.07E-08 |
| GO.0072358 | cardiovascular system development               | 29    | 7.69E-08 |
| GO.0072359 | circulatory system development                  | 29    | 7.69E-08 |
| GO.0040012 | regulation of locomotion                       | 27    | 9.01E-08 |
| GO.0051240 | positive regulation of multicellular organismal process | 38    | 9.01E-08 |
| GO.0010033 | response to organic substance                   | 53    | 1.83E-07 |
| GO.0048514 | blood vessel morphogenesis                      | 20    | 1.88E-07 |
| GO.0051726 | regulation of cell cycle                        | 31    | 1.93E-07 |
| GO.0042221 | response to chemical                           | 68    | 2.21E-07 |
| GO.0048468 | cell development                                | 41    | 2.60E-07 |
| GO.0045766 | positive regulation of angiogenesis             | 12    | 2.79E-07 |
| GO.0048583 | regulation of response to stimulus              | 63    | 2.79E-07 |
| GO.0014070 | response to organic cyclic compound             | 28    | 2.83E-07 |
| GO.0008284 | positive regulation of cell proliferation       | 28    | 2.92E-07 |
| GO.0071407 | cellular response to organic cyclic compound    | 19    | 3.23E-07 |
| GO.0071840 | cellular component organization or biogenesis   | 79    | 5.43E-07 |
| GO.0010941 | regulation of cell death                        | 38    | 7.50E-07 |
| GO.0032879 | regulation of localization                      | 49    | 7.79E-07 |
| GO.0001525 | angiogenesis                                    | 17    | 1.04E-06 |
| GO.0051128 | regulation of cellular component organization   | 47    | 1.04E-06 |
| GO.0009966 | regulation of signal transduction               | 50    | 1.23E-06 |
| GO.0006928 | movement of cell or subcellular component       | 35    | 1.73E-06 |
| GO.2000026 | regulation of multicellular organismal development | 38    | 1.86E-06 |
| GO.0043065 | positive regulation of apoptotic process        | 22    | 2.16E-06 |
| GO.0065009 | regulation of molecular function                | 53    | 2.16E-06 |
| GO.0071495 | cellular response to endogenous stimulus        | 30    | 2.37E-06 |
| GO.0019220 | regulation of phosphate metabolic process       | 37    | 3.60E-06 |

(Continued)
both the transactivation dependent pathways and may play a role in the convergence of the two signalling pathways to regulate the same biological processes.

Our lab has focused on GAG elongation because of its association with atherosclerosis but also because signalling pathways for GAG elongation are distinct from their signalling common responses such as protein signalling and cell proliferation [14–16, 71]. Never the less GAG elongation has also been an excellent response to characterise transactivation dependent signalling and in that context our work has shown how transactivation dependent signalling makes a major contribution to PAR-1 signalling.

Transactivation dependent signalling is associated with genes regulating vasculature development

To assess the processes influenced by transactivation dependent signalling, the differentially expressed genes were subjected to functional enrichment analysis based on their GO annotations. The biological processes most commonly enriched by the three treatments were linked with vascular development (GO.0072358 Table 7). There were 29 genes associated with cardiovascular system development in thrombin transactivation of the EGFR (Table 4); 28 genes in thrombin transactivation of the TGFBR1 (Table 5) and 31 genes in thrombin transactivation of both the TGFBR1 and EGFR (Table 6). All the genes were up regulated by thrombin when compared to basal and down regulated in the presence of AG1478 with the exception of EGR1, HES1, NR4A1, PDGFB, RHOB, SPHK1 and TIPARP (Table 7). In the presence of thrombin and TGFBR1 antagonist, SB431542, most of the genes associated with cardiovascular system development were down regulated with the exception of EGR1 and TIPARP (Table 7). When looking at dual transactivation dependent signalling associated with cardiovascular system development all genes apart from EGR1, HES1 ID1, KLFS, NR4A1, PTGS2 and RHOB were down regulated as compared to thrombin stimulation alone (Table 7).

The EGR1 (early growth response 1) gene associated with cardiovascular system development was regulated by the three treatments when compared to thrombin (Table 7). EGR1 is involved in the development of atherosclerotic lesions and has been shown to play a role in regulating neointimal thickening in response to vascular injury [72–75]. Thrombin mediated GAG chain elongation evaluated by the mRNA expression of CHST11 and CHSY1 was inhibited in the presence of antagonists to the EGFR and TGFBR1 [33]. However the RNA-Sequencing results show that with treatment of the receptor antagonists in the presence of the thrombin there is an increase in the expression of the EGR1 gene, this may be due to earlier work looking at the pre-inflammatory phase of atherosclerosis. The EGR1 gene is commonly involved in the neointimal thickening which is in the inflammatory phase of atherogenesis.

The ANKRD1 (Ankyrin Repeat Domain 1) gene belongs to the conserved muscle Ankyrin repeat family and is induced in response to inflammation, injury and response to cell stress [76, 77]. The ANKRD1 gene is amongst the differentially expressed genes associated with vascular development. The ANKRD1 gene was involved in the transactivation of the EGFR and the TGFBR1 (Table 7). ANKRD1 is directly mediated via TGF-β mediated signalling as the ANKRD1 promotor region contains a Smad binding motif [78, 79]. The ANKRD1 gene is

| GO ID   | GO Term                                      | Count | FDR       |
|---------|----------------------------------------------|-------|-----------|
| GO.0009605 | response to external stimulus                | 42    | 3.92E-06  |
| GO.0048519 | negative regulation of biological process    | 70    | 4.03E-06  |
| GO.1902531 | regulation of intracellular signal transduction | 35    | 4.43E-06  |

https://doi.org/10.1371/journal.pone.0180842.t004

Table 4. (Continued)
Table 5. The top 50 gene ontology terms in the analysis of genes expressed in thrombin transactivation of the TGFBR1.

| GO ID   | GO Term                                        | Count | FDR       |
|---------|-----------------------------------------------|-------|-----------|
| GO.0051094 | positive regulation of developmental process     | 34    | 1.63E-08  |
| GO.0009653 | anatomical structure morphogenesis              | 46    | 1.66E-08  |
| GO.0030334 | regulation of cell migration                    | 25    | 1.66E-08  |
| GO.0070887 | cellular response to chemical stimulus          | 48    | 1.66E-08  |
| GO.0071310 | cellular response to organic substance          | 43    | 1.66E-08  |
| GO.0072358 | cardiovascular system development               | 28    | 1.66E-08  |
| GO.0072359 | circulatory system development                  | 28    | 1.66E-08  |
| GO.0019220 | regulation of phosphate metabolic process       | 37    | 8.63E-08  |
| GO.0031399 | regulation of protein modification process      | 38    | 8.63E-08  |
| GO.0051239 | regulation of multicellular organismal process  | 47    | 9.10E-08  |
| GO.0048668 | cell development                                | 38    | 1.03E-07  |
| GO.1902531 | regulation of intracellular signal transduction | 35    | 1.04E-07  |
| GO.0030335 | positive regulation of cell migration           | 18    | 1.35E-07  |
| GO.0051270 | regulation of cellular component movement       | 25    | 1.42E-07  |
| GO.0048519 | negative regulation of biological process       | 65    | 2.26E-07  |
| GO.0042981 | regulation of apoptotic process                 | 34    | 2.67E-07  |
| GO.0040012 | regulation of locomotion                        | 24    | 2.81E-07  |
| GO.0043067 | regulation of programmed cell death             | 34    | 2.81E-07  |
| GO.009888  | tissue development                              | 36    | 3.06E-07  |
| GO.0030154 | cell differentiation                            | 53    | 4.72E-07  |
| GO.0051240 | positive regulation of multicellular organismal process | 33 | 4.72E-07 |
| GO.0050793 | regulation of developmental process             | 42    | 4.79E-07  |
| GO.1901342 | regulation of vasculature development           | 14    | 5.83E-07  |
| GO.0007507 | heart development                               | 19    | 7.20E-07  |
| GO.0045597 | positive regulation of cell differentiation      | 25    | 7.20E-07  |
| GO.0009966 | regulation of signal transduction               | 45    | 7.39E-07  |
| GO.0009892 | negative regulation of metabolic process        | 46    | 8.03E-07  |
| GO.0065009 | regulation of molecular function                 | 48    | 8.03E-07  |
| GO.0042221 | response to chemical                            | 58    | 1.34E-06  |
| GO.0042325 | regulation of phosphorylation                   | 31    | 1.34E-06  |
| GO.0048583 | regulation of response to stimulus              | 54    | 1.34E-06  |
| GO.0010033 | response to organic substance                   | 45    | 1.48E-06  |
| GO.0044057 | regulation of system process                    | 18    | 1.60E-06  |
| GO.0051128 | regulation of cellular component organization   | 41    | 2.63E-06  |
| GO.0051726 | regulation of cell cycle                        | 26    | 3.13E-06  |
| GO.0016477 | cell migration                                  | 23    | 3.49E-06  |
| GO.0001932 | regulation of protein phosphorylation           | 29    | 3.61E-06  |
| GO.0045937 | positive regulation of phosphate metabolic process | 26 | 3.67E-06 |
| GO.0001568 | blood vessel development                        | 18    | 3.71E-06  |
| GO.0048869 | cellular developmental process                   | 52    | 4.09E-06  |
| GO.0050790 | regulation of catalytic activity                | 41    | 4.57E-06  |
| GO.0071407 | cellular response to organic cyclic compound    | 16    | 4.58E-06  |
| GO.2000026 | regulation of multicellular organismal development | 33   | 5.80E-06  |
| GO.0048523 | negative regulation of cellular process         | 58    | 5.83E-06  |
| GO.0051246 | regulation of protein metabolic process         | 43    | 6.58E-06  |
| GO.0001944 | vasculature development                         | 18    | 6.70E-06  |
| GO.0042127 | regulation of cell proliferation                 | 32    | 7.24E-06  |

(Continued)
associated with the actin cytoskeleton signalling network [80], in our model thrombin mediated transactivation of the TGFBR1 activates Rho/ROCK signalling via cytoskeletal rearrangement leading to the activation of cell surface integrins [15]. Thus demonstrating a potential signalling pathway for the activation of the ANKRD1 gene via thrombin transactivation of the TGFBR1. The role of ANKRD1 downstream of the EGFR is unknown, however ANKRD1 is induced by stress activated kinases [81–83] hence we speculate that thrombin mediated transactivation of the EGFR induces the expression of ANKRD1 via the activation of downstream stress activated MAPKs (Erk, p38 and Jnk). MAPK mediated Smad2 linker region phosphorylation correlates with proteoglycan synthesis and GAG chain elongation [84, 85]. In VSMCs thrombin mediated transactivation of the EGFR and TGFBR1 result in the phosphorylation of transcription factor Smad2 in the linker region. Thus GPCR mediated expression of ANKRD1 may signal via Smad2 linker region dependent pathways.

To validate the data from the RNA-Seq experiments we investigated thrombin mediated mRNA and protein expression of ANKRD1. Thrombin treated CASMCs lead to a 1.5-fold increase in ANKRD1 mRNA expression (Fig 8A). In the presence of TGFBR1 antagonist, SB431542 and EGFR antagonist, AG1478 individually and together they completely abolished thrombin mediated mRNA expression of ANKRD1 (Fig 8A). The protein expression follows a similar pattern, treatment with thrombin increased ANKDR1 protein levels to 1.5-fold (Fig 8B) in the presence of the two receptor antagonists thrombin mediated ANKDR1 protein expression is completely inhibited. Thus these results validate the genes that were modulated in this RNA-Seq screen.

Conclusions

GPCRs are one of the most successful class of drug targets on the human genome for the treatment of a variety of diseases [86, 87]. Hence the role of GPCR signalling is of great interest to medical research. GPCRs signal in three main mechanisms, which includes signalling via G proteins to secondary messenger intermediates and via utilization of the signalling pathway and via the utilization of a β-arrestin molecule both which have been extensively reviewed [19, 88]. The third GPCR signalling pathway is via transactivation of PTKR and via transactivation of S/TKR. We subsequently described S/TKR transactivation but again the contribution to overall GPCR signalling was unknown. Hence in this present study, the aim was to determine the contribution of dual transactivation of GPCR mediated signalling by utilizing RNA sequencing to facilitate the identification of the genes regulated by these two transactivation pathways. Using this approach, we have uncovered that thrombin mediated signalling results in 293 differentially expressed genes of these genes approximately 50% of the signalling is occurring via transactivation dependent signalling. Using this approach we have also uncovered that transactivation of the TGFBR1 is as equally important as the transactivation of the EGFR noting that the TGFBR1 transactivation pathway has not yet been as extensively researched.

Hannan et al. [39] used a siRNA approach studied 720 kinase genes associated with Angiotensin II transactivation of the EGFR. Knockdown of 3 genes, TRIO, BMX and CHKA
| GO ID   | GO Term                                           | Count | FDR       |
|---------|--------------------------------------------------|-------|-----------|
| GO.0070887  | cellular response to chemical stimulus           | 63    | 1.11E-12  |
| GO.0071310  | cellular response to organic substance           | 56    | 1.11E-12  |
| GO.0051094  | positive regulation of developmental process    | 39    | 9.25E-10  |
| GO.0010033  | response to organic substance                    | 58    | 4.30E-09  |
| GO.0030334  | regulation of cell migration                     | 28    | 4.30E-09  |
| GO.0042221  | response to chemical                            | 74    | 4.30E-09  |
| GO.0048468  | cell development                                 | 45    | 1.04E-08  |
| GO.0072358  | cardiovascular system development                | 31    | 1.08E-08  |
| GO.0072359  | circulatory system development                   | 31    | 1.08E-08  |
| GO.0051240  | positive regulation of multicellular organismal process | 40    | 2.15E-08  |
| GO.0042981  | regulation of apoptotic process                  | 40    | 4.01E-08  |
| GO.0051239  | regulation of multicellular organismal process   | 54    | 4.01E-08  |
| GO.0043067  | regulation of programmed cell death             | 40    | 4.27E-08  |
| GO.0050793  | regulation of developmental process             | 50    | 5.47E-08  |
| GO.0030335  | positive regulation of cell migration            | 20    | 6.37E-08  |
| GO.0051270  | regulation of cellular component movement       | 28    | 8.18E-08  |
| GO.0071407  | cellular response to organic cyclic compound     | 20    | 1.08E-07  |
| GO.0071495  | cellular response to endogenous stimulus         | 33    | 1.14E-07  |
| GO.1901342  | regulation of vasculature development            | 16    | 1.21E-07  |
| GO.0009653  | anatomical structure morphogenesis               | 49    | 1.22E-07  |
| GO.0014070  | response to organic cyclic compound              | 29    | 1.22E-07  |
| GO.0040012  | regulation of locomotion                         | 27    | 1.27E-07  |
| GO.0001568  | blood vessel development                         | 22    | 1.37E-07  |
| GO.0051726  | regulation of cell cycle                         | 31    | 2.93E-07  |
| GO.0048519  | negative regulation of biological process        | 74    | 3.54E-07  |
| GO.0010941  | regulation of cell death                         | 39    | 4.20E-07  |
| GO.0045597  | positive regulation of cell differentiation      | 28    | 5.27E-07  |
| GO.0048522  | positive regulation of cellular process          | 74    | 1.00E-06  |
| GO.0048518  | positive regulation of biological process        | 81    | 1.01E-06  |
| GO.0042127  | regulation of cell proliferation                 | 38    | 1.22E-06  |
| GO.0051716  | cellular response to stimulus                    | 90    | 1.38E-06  |
| GO.0001944  | vasculature development                          | 21    | 1.41E-06  |
| GO.0060548  | negative regulation of cell death                | 29    | 1.41E-06  |
| GO.0051241  | negative regulation of multicellular organismal process | 30    | 1.45E-06  |
| GO.1901698  | response to nitrogen compound                    | 28    | 1.95E-06  |
| GO.0045765  | regulation of angiogenesis                       | 14    | 1.97E-06  |
| GO.0009892  | negative regulation of metabolic process         | 51    | 2.92E-06  |
| GO.0048583  | regulation of response to stimulus               | 61    | 3.06E-06  |
| GO.0032879  | regulation of localization                       | 48    | 3.55E-06  |
| GO.0009888  | tissue development                               | 38    | 3.89E-06  |
| GO.0009890  | negative regulation of biosynthetic process      | 36    | 4.25E-06  |
| GO.0033993  | response to lipid                                | 26    | 4.25E-06  |
| GO.0043069  | negative regulation of programmed cell death     | 27    | 4.39E-06  |
| GO.0051128  | regulation of cellular component organization    | 46    | 4.39E-06  |
| GO.0010629  | negative regulation of gene expression           | 36    | 4.58E-06  |
| GO.0044057  | regulation of system process                     | 19    | 4.88E-06  |
| GO.0048514  | blood vessel morphogenesis                        | 18    | 5.31E-06  |
| GO.0022603  | regulation of anatomical structure morphogenesis | 27    | 5.70E-06  |
| GO.1904018  | positive regulation of vasculature development   | 11    | 5.71E-06  |
| GO.0010632  | regulation of epithelial cell migration           | 12    | 5.80E-06  |

https://doi.org/10.1371/journal.pone.0180842.t006
revealed that their activity is required for Angiotensin II mediated transactivation of the EGFR in human mammary epithelial cells [39]. This RNA-Seq sequencing study we explored all the
that were involved in GPCR mediated transactivation of the EGFR and TGFBR1 in human VSMCs. Although the two transactivation signalling pathways have been reported as to be mechanistically distinct [14, 15] this study shows that these two pathways share in over 65% of the differentially expressed genes. The transactivation dependent signalling pathways shared in over 55% of its top 50 enriched terms, with a majority of these GO terms associated with cardiovascular system development.

The two transactivation dependent signalling pathways share in over 65% of common differentially expressed genes. The most regulated genes of these transactivation mediated
pathways are involved in molecular functions such as cytokine activity which controls cell growth survival and differentiation. Cytokine activity is involved in different aspects of cancer, development, treatment and prognosis [89–91]. The EGFR [92–94] and the TGFBR1 [95–97] signalling pathways alone play a role in cancer development. Both the EGFR and TGFBR1 signalling pathways share a common transcription factor, Smad2 linker region. The Smad2 linker region is also associated with other pathophysiological conditions which include but are not limited to proteoglycan
synthesis and GAG chain elongation associated with atherosclerosis development [84, 85]. Thus showing that the linker region of the Smad2 may be a transcription factor of interest for to study different biological process occurring via thrombin mediated transactivation of both the EGFR and TGFBR1.

In summary, by generating and utilizing high throughput RNA-Seq data, we have identified that GPCR signalling via transactivation of either of the EGFR or TGFBR1 account for 50% of GPCR signalling. We have identified that these two pathways share in regulation of over 65% of genes of which a majority are involved in the development of the vasculature. This work provides the platform for investigating the molecular basis for transactivation dependent signalling and provides proof that genome wide studies can offer powerful insights into this process.

Table 7. List of genes and respective fold change of expression associated with gene ontology term cardiovascular development. The differentially expressed genes with no fold change presented in the table did not reach the statistical significance cut off ($P<0.01$ and Log2FC$>0.7$)

| Gene ID          | Gene Name | Thr  | Thr+AG | Thr+SB | Thr+SB+AG |
|------------------|-----------|------|--------|--------|-----------|
| ENSG00000148677  | ANKRD1    | 3.514| 0.612  | 0.962  | 0.352     |
| ENSG00000183337  | BCOR      | 1.646|        | 0.533  | 0.543     |
| ENSG00000118523  | CTGF      | 2.662| 1.251  | 0.901  | 0.933     |
| ENSG00000142871  | CYR61     | 2.631| 2.133  | 2.298  | 2.024     |
| ENSG00000164741  | DLC1      | 1.755|        | 0.731  | 0.901     |
| ENSG00000078401  | EDN1      | 5.188| 1.013  | 0.458  | 0.547     |
| ENSG00000120738  | EGR1      | 1.394| 4.249  | 4.505  | 3.684     |
| ENSG00000196159  | FAT4      | 1.292|        | 0.601  |           |
| ENSG00000176692  | FOXC2     | 1.671|        |        | 0.694     |
| ENSG00000170961  | HAS2      | 2.047| 0.544  |        | 0.293     |
| ENSG00000114315  | HES1      | 3.058| 3.152  | 1.154  | 3.115     |
| ENSG00000100644  | HIF1A     | 1.471| 0.639  | 0.627  |           |
| ENSG00000125968  | ID1       | 4.482| 0.626  | 0.775  | 0.194     |
| ENSG00000115738  | ID2       | 1.302| 0.544  | 0.337  |           |
| ENSG00000117318  | ID3       | 3.315| 1.153  | 0.814  | 0.549     |
| ENSG00000121361  | KCNJ8     | 2.129| 0.706  | 0.894  | 0.637     |
| ENSG00000102554  | KLF5      | 2.679| 1.933  | 2.141  | 2.690     |
| ENSG00000085276  | MECOM     | 1.673| 0.437  | 0.488  | 0.486     |
| ENSG00000164134  | NAA15     | 1.639| 0.793  | 0.804  |           |
| ENSG00000162614  | NEXN      | 1.815| 0.821  | 0.876  | 0.886     |
| ENSG00000086991  | NOX4      | 2.015| 0.566  | 0.347  | 0.423     |
| ENSG00000123358  | NR4A1     | 14.061| 19.477| 10.102| 16.838    |
| ENSG00000180914  | OXTR      | 2.303| 0.854  | 0.616  | 0.746     |
| ENSG00000139650  | PCDH10    | 1.322| 0.667  | 0.613  | 0.581     |
| ENSG00000100311  | PDGFB     | 6.773| 6.991  | 1.294  | 2.835     |
| ENSG00000073756  | PTGS2     | 3.350| 3.195  | 2.066  | 3.791     |
| ENSG00000127329  | PTPRB     | 1.731|        | 0.829  |           |
| ENSG00000143878  | RHOB      | 2.416| 2.434  | 1.028  | 2.691     |
| ENSG00000124216  | SNA11     | 1.783|        | 0.650  | 1.174     |
| ENSG00000176170  | SPHK1     | 2.078| 2.630  | 1.731  | 1.424     |
| ENSG00000120156  | TEK       | 1.936| 0.543  | 0.549  | 0.576     |
| ENSG00000163659  | TIPARP    | 1.416| 2.162  | 2.084  |           |
| ENSG0000006327   | TNFRSF12A | 1.578|        | 1.309  |           |

https://doi.org/10.1371/journal.pone.0180842.t007
Author Contributions

Conceptualization: Nitin Mantri, Wenhua Zheng, Peter J Little, Narin Osman.

Data curation: Danielle Kamato, Venkata Vijayanand Bhaskarala, Tae Gyu Oh, Dora Ling, Reearna Janke.

Formal analysis: Danielle Kamato, Venkata Vijayanand Bhaskarala, Tae Gyu Oh, Dora Ling, Reearna Janke.

Investigation: Danielle Kamato, Venkata Vijayanand Bhaskarala, Dora Ling, Reearna Janke.

Methodology: Danielle Kamato, Nitin Mantri, Peter J Little.

Project administration: Nitin Mantri, Wenhua Zheng, Peter J Little, Narin Osman.

Software: Venkata Vijayanand Bhaskarala, Tae Gyu Oh.

Supervision: Nitin Mantri, Peter J Little, Narin Osman.

Validation: Danielle Kamato, Venkata Vijayanand Bhaskarala, Dora Ling, Reearna Janke.

Visualization: Danielle Kamato, Peter J Little, Narin Osman.

Writing – original draft: Danielle Kamato, Peter J Little, Narin Osman.

Writing – review & editing: Danielle Kamato, Nitin Mantri, Wenhua Zheng, Peter J Little, Narin Osman.

References

1. Tang XL, Wang Y, Li DL, Luo J, Liu MY. Orphan G protein-coupled receptors (GPCRs): biological functions and potential drug targets. Acta pharmacologica Sinica. 2012; 33(3):363–71. https://doi.org/10.1038/aps.2011.210 PMID: 22367282; PubMed Central PMCID: PMC4077139.
2. Zhang X, Eggert US. Non-traditional roles of G protein-coupled receptors in basic cell biology. Molecular bioSystems. 2013; 9(4):586–95. https://doi.org/10.1039/c2mb25429h PMID: 23247090; PubMed Central PMCID: PMC3628546.

3. Spehr M, Munger SD. Olfactory receptors: G protein-coupled receptors and beyond. J Neurochem. 2009; 109(6):1570–83. https://doi.org/10.1111/j.1471-4159.2009.06085.x PMID: 19383089; PubMed Central PMCID: PMCPMC4455932.

4. McCudden CR, Hains MD, Kimple RJ, Siderovski DP, Willard FS. G-protein signaling: back to the future. Cell Mol Life Sci. 2005; 62(5):551–77. PMID: 15747061. https://doi.org/10.1007/s00018-004-4462-3

5. Morris AJ, Malbon CC. Physiological regulation of G protein-linked signaling. Physiol Rev. 1999; 79(4):1373–430. PMID: 10508237.

6. Catanzaro DF, Frishman WH. Angiotensin receptor blockers for management of hypertension. South Med J. 2010; 103(7):669–73. Epub 2010/06/10. https://doi.org/10.1097/SMJ.0b013e3181e1e2da PMID: 20531060.

7. Bristow MR. beta-adrenergic receptor blockade in chronic heart failure. Circulation. 2000; 101(5):558–69. Epub 2000/02/09. PMID: 10662755.

8. Packer M. Current role of beta-adrenergic blockers in the management of chronic heart failure. Am J Med. 2001; 110 Suppl 7A:81S–94S. Epub 2001/05/04. PMID: 11334782.

9. Gutkind JS. Cell growth control by G protein-coupled receptors: from signal transduction to signal integration. Oncogene. 1998; 17(11 Reviews):1331–42. Epub 1998/10/21. https://doi.org/10.1038/sj.onc.1202186 PMID: 9779981.

10. Luttrell LM. Reviews in molecular biology and biotechnology: transmembrane signaling by G protein-coupled receptors. Mol Biotechnol. 2008; 39(3):239–64. https://doi.org/10.1007/s12033-008-9031-1 PMID: 18240029.

11. Katritch V, Cherezov V, Stevens RC. Structure-function of the G protein-coupled receptor superfamily. Annu Rev Pharmacol Toxicol. 2013; 53:531–56. https://doi.org/10.1146/annurev-pharmtox-032112-135923; PubMed Central PMCID: PMCPMC3540149.

12. Lefkowitz RJ, Shenoy SK. Transduction of receptor signals by beta-arrestins. Science. 2005; 308(5721):512–7. PMID: 15845844. https://doi.org/10.1126/science.1109237

13. Daub H, Weiss FU, Wallasch C, Ullrich A. Role of transactivation of the EGF receptor in signalling by G-protein-coupled receptors. Nature. 1996; 379(6565):557–60. PMID: 8596637. https://doi.org/10.1038/379557a0

14. Burch ML, Ballinger ML, Yang SN, Getachew R, Itman C, Loveland K, et al. Thrombin stimulation of proteoglycan synthesis in vascular smooth muscle is mediated by protease-activated receptor-1 trans-activation of the transforming growth factor beta type I receptor. J Biol Chem. 2010; 285(35):26798–805. Epub 2010/06/24. https://doi.org/10.1074/jbc.M109.092767 PMID: 20571025; PubMed Central PMCID: PMC2930678.

15. Burch ML, Getachew R, Osman N, Febbraio MA, Little PJ. Thrombin mediated proteoglycan synthesis utilizes both protein tyrosine kinase and serine/threonine kinase receptor transactivation in vascular smooth muscle cells. J Biol Chem. 2013. Epub 2013/01/22. https://doi.org/10.1074/jbc.M112.400259 PMID: 23335513.

16. Little PJ, Burch ML, Getachew R, Al-aryahi S, Osman N. Endothelin-1 stimulation of proteoglycan synthesis in vascular smooth muscle is mediated by endothelin receptor transactivation of the transforming growth factor-[beta]-type I receptor. J Cardiovasc Pharmacol. 2010; 56(4):360–8. Epub 2010/07/14. https://doi.org/10.1097/FJC.0b013e3181e6811 PMID: 20625315.

17. Jenkins RG, Su X, Su G, Scotton CJ, Camerer E, Laurent GJ, et al. Ligation of protease-activated receptor 1 enhances alpha(v)beta6 integrin-dependent TGF-beta activation and promotes acute lung injury. J Clin Invest. 2006; 116(6):1606–14. Epub 2006/05/20. https://doi.org/10.1172/JCI27183 PMID: 16710477; PubMed Central PMCID: PMC1462943.

18. Xu MY, Porte J, Knox AJ, Weinreb PH, Maher TM, Violette SM, et al. Lysoosphatidic acid induces alphavbeta6 integrin-mediated TGF-beta activation via the LPA2 receptor and the small G protein G alpha(q). Am J Pathol. 2009; 174(4):1264–79. Epub 2009/01/17. https://doi.org/10.2353/apth.2009.080162 PMID: 19147812; PubMed Central PMCID: PMC2671389.

19. Ferguson SS, Barak LS, Zhang J, Caron MG. G-protein-coupled receptor regulation: role of G-protein-coupled receptor kinases and arrestins. Can J Physiol Pharmacol. 1996; 74(10):1095–110. Epub 1996/10/01. PMID: 9022629.

20. Daub H, Wallasch C, Lankenau A, Herrlich A, Ullrich A. Signal characteristics of G protein-transactivated EGF receptor. Embo J. 1997; 16(23):7032–44. Epub 1998/01/31. https://doi.org/10.1093/emboj/16.23.7032 PMID: 9384582; PubMed Central PMCID: PMC1170306.
21. Wynne BM, Chiao CW, Webb RC. Vascular Smooth Muscle Cell Signaling Mechanisms for Contraction to Angiotensin II and Endothelin-1. J Am Soc Hypertens. 2009; 3(2):84–95. https://doi.org/10.1016/j.jash.2008.09.002 PMID: 20161229; PubMed Central PMCID: PMC2704475.

22. Murasawa S, Mori Y, Nozawa Y, Gotoh N, Shibuya M, Masaki H, et al. Angiotensin II type 1 receptor-induced extracellular signal-regulated protein kinase activation is mediated by Ca2+/calmodulin-dependent transactivation of epidermal growth factor receptor. Circ Res. 1998; 82(12):1336–48. Epub 1998/07/02. PMID: 9648731.

23. Lautrette A, Li S, Alili R, Sunnarborg SW, Burtin M, Lee DC, et al. Angiotensin II and EGF receptor cross-talk in chronic kidney diseases: a new therapeutic approach. Nat Med. 2005; 11(8):867–74. https://doi.org/10.1038/nm1275 PMID: 16041383.

24. Thomas WG, Qian H. Arresting angiotensin type 1 receptors. Trends Endocrinol Metab. 2003; 14(3):130–6. Epub 2003/04/03. PMID: 12670739.

25. Thomas WG, Brandenburger Y, Autelitano DJ, Pham T, Qian H, Hannan RD. Adenoviral-directed expression of the type 1A angiotensin receptor promotes cardiomyocyte hypertrophy via transactivation of the epidermal growth factor receptor. Circ Res. 2002; 90(2):135–42. PMID: 11834705.

26. George AJ, Thomas WG, Hannan RD. The renin-angiotensin system and cancer: old dog, new tricks. Nat Rev Cancer. 2010; 10(11):745–59. https://doi.org/10.1038/nrc2945 PMID: 20966920.

27. Belcheva MM, Haas PD, Tan Y, Heaton VM, Coscia CJ. The fibroblast growth factor receptor is at the site of convergence between mu-opioid receptor and growth factor signaling pathways in rat C6 glioma cells. J Pharmacol Exp Ther. 2002; 303(3):909–18. Epub 2002/11/20. https://doi.org/10.1124/jpet.102.038554 PMID: 12438509; PubMed Central PMCID: PMC2587035.

28. Heeneman S, Haendeler J, Saito Y, Ishida M, Berk BC. Angiotensin II induces transactivation of two different populations of the platelet-derived growth factor beta receptor. Key role for the p66 adaptor protein Shc. J Biol Chem. 2000; 275(21):15926–32. https://doi.org/10.1074/jbc.M909616199 PMID: 10748142.

29. Rao GN, Delafontaine P, Runge MS. Thrombin stimulates phosphorylation of insulin-like growth factor-1 receptor, insulin receptor substrate-1, and phospholipase C-gamma 1 in rat aortic smooth muscle cells. J Biol Chem. 1995; 270(46):27871–5. PMID: 7499260.

30. Little PJ, Ivey ME, Osman N. Endothelin-1 actions on vascular smooth muscle cell functions as a target for the prevention of atherosclerosis. Curr Vasc Pharmacol. 2008; 6(3):195–203. Epub 2008/08/05. PMID: 18673159.

31. Chung H, Ramachandran R, Hollenberg MD, Muruve DA. Proteinase-activated receptor-2 transactivation of epidermal growth factor receptor and transforming growth factor-beta receptor signaling pathways contributes to renal fibrosis. J Biol Chem. 2013; 288(52):37319–31. https://doi.org/10.1074/jbc.M113.492793 PMID: 24259040; PubMed Central PMCID: PMC3873584.

32. Liu Y, Ren W, Warburton R, Toksoz D, Fanburg BL. Serotonin induces Rho/ROCK-dependent activation of Smads 1/5/8 in pulmonary artery smooth muscle cells. FASEB J. 2009; 23(7):2299–306. Epub 2009/02/27. https://doi.org/10.1096/fj.08-127910 PMID: 19244313.

33. Kamato D, Thach L, Getachew R, Burch M, Hollenberg MD, Zheng W, et al. Protease activated receptor-1 mediated dual kinase receptor transactivation stimulates the expression of glycosaminoglycan synthesizing genes. Cell Signal. 2016; 28(1):110–9. https://doi.org/10.1016/j.cellsig.2015.11.003 PMID: 26548632.

34. Giannopoulou EG, Elemento O, Ivashkov LB. Use of RNA sequencing to evaluate rheumatic disease patients. Arthritis Res Ther. 2015; 17:167. https://doi.org/10.1186/s13075-015-0877-3 PMID: 26126608; PubMed Central PMCID: PMC4488125.

35. Xu J, Sun J, Chen J, Wang L, Li A, Helm M, et al. RNA-Seq analysis implicates dysregulation of the immune system in schizophrenia. BMC Genomics. 2012; 13 Suppl 8:S2. https://doi.org/10.1186/1471-2164-13-S8-S2 PMID: 23282246; PubMed Central PMCID: PMC3535722.

36. Celic CJ, Houvras Y, Jane-Valbuena J, Bilodeau S, Orlando DA, Battisti V, et al. The histone methyltransferase SETDB1 is recurrently amplified in melanoma and accelerates its onset. Nature. 2011; 471(7339):513–7. https://doi.org/10.1038/nature09806 PMID: 21430779; PubMed Central PMCID: PMC3348545.

37. Steidl C, Shah SP, Woolcock BW, Rui L, Kawahara M, Farinha P, et al. MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers. Nature. 2011; 471(7338):377–81. https://doi.org/10.1038/nature09754 PMID: 21368758; PubMed Central PMCID: PMC3902849.

38. Briggs TA, Rice GJ, Daly S, Urquhart J, Gornall H, Bader-Meunier B, et al. Tartrate-resistant acid phosphatase deficiency causes a bone dysplasia with autoimmunity and a type I interferon expression signature. Nat Genet. 2011; 43(2):127–31. https://doi.org/10.1038/ng.748 PMID: 21217755; PubMed Central PMCID: PMC3030921.
39. George AJ, Purdue BW, Gould CM, Thomas DW, Handoko Y, Qian H, et al. A functional siRNA screen identifies genes modulating angiotensin II-mediated EGFR transactivation. J Cell Sci. 2013; 126(Pt 23):5377–90. https://doi.org/10.1242/jcs.128280 PMID: 24046455; PubMed Central PMCID: PMC3843137.

40. Kim D, Pertea G, Trapnell C, Pimentel H, Kelley R, Salzberg SL. TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions. Genome biology. 2013; 14(4):1.

41. Langmead B, Salzberg SL. Fast gapped-read alignment with Bowtie 2. Nature methods. 2012; 9(4):357–9. https://doi.org/10.1038/nmeth.1923 PMID: 22388286

42. Anders S, Pyl PT, Huber W. HTSeq—A Python framework to work with high-throughput sequencing data. Bioinformatics. 2014;btu638.

43. Robinson MD, McCarthy DJ, Smyth GK. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics. 2010; 26(1):139–40. https://doi.org/10.1093/bioinformatics/btp616 PMID: 19910308; PubMed Central PMCID: PMC2796818.

44. Team RC. R: A language and environment for statistical computing. 2013.

45. Szklarczyk D, Franceschini A, Wyder S, Forslund K, Heller D, Huerta-Cepas J, et al. STRING v10: protein-protein interaction networks, integrated over the tree of life. Nucleic acids research. 2015; 43(Database issue):D447–52. https://doi.org/10.1093/nar/gku1003 PMID: 25352553; PubMed Central PMCID: PMC4383874.

46. Bardou P, Mariette J, Escudie F, Djemiel C, Klopp C. jvenn: an interactive Venn diagram viewer. BMC Bioinformatics. 2014; 15:293. https://doi.org/10.1186/1471-2105-15-293 PMID: 25176396; PubMed Central PMCID: PMCPMC4261873.

47. Djebali S, Davis CA, Merkel A, Dobin A, Lassmann T, Mortazavi A, et al. Landscape of transcription in human cells. Nature. 2012; 489(7414):101–8. https://doi.org/10.1038/nature11233 PMID: 22955620; PubMed Central PMCID: PMC3684276.

48. Wang Z, Gerstein M, Snyder M. RNA-Seq: a revolution tool for transcriptomics. Nature reviews Genetics. 2009; 10(1):57–63. https://doi.org/10.1038/nrg2484 PMID: 19015660; PubMed Central PMCID: PMC2949280.

49. Burch ML, Getachew R, Osman N, Febbraio MA, Little PJ. Thrombin-mediated proteoglycan synthesis utilizes both protein-tyrosine kinase and serine/threonine kinase receptor transactivation in vascular smooth muscle cells. J Biol Chem. 2013; 288(10):7410–9. Epub 2013/01/22. https://doi.org/10.1074/jbc.M112.400259 PMID: 23335513; PubMed Central PMCID: PMC3591648.

50. Smiljanic K, Obrazovic M, Jovanovic A, Djordjevic J, Dobutovic B, Jevremovic D, et al. Thrombin stimulates VSMC proliferation through an EGFR-dependent pathway: involvement of MMP-2. Mol Cell Biochem. 2014; 396(1–2):147–60. https://doi.org/10.1007/s11010-014-2151-y PMID: 25047892.

51. Wang Z. Transactivation of Epidermal Growth Factor Receptor by G Protein-Coupled Receptors: Recent Progress, Challenges and Future Research. Int J Mol Sci. 2016; 17(1). https://doi.org/10.3390/ijms17010095 PMID: 26771606; PubMed Central PMCID: PMC4730337.

52. Yu G, Liang X, Xie X, Yang T, Sun M, Zhao S. Apoptosis, myocardial fibrosis and angiotensin II in the left ventricle of hypertensive rats treated with fosinopril or losartan. Chin Med J (Engl). 2002; 115(9):1287–91. Epub 2002/11/02. PMID: 12411096.

53. Gui T, Sun Y, Shimokado A, Muragaki Y. The Roles of Mitogen-Activated Protein Kinase Pathways in TGF-beta-Induced Epithelial-Mesenchymal Transition. Journal of signal transduction. 2012; 2012:289243. https://doi.org/10.1155/2012/289243 PMID: 22363839; PubMed Central PMCID: PMC3272823.

54. Yamaguchi K, Shirakabe K, Shibuya H, Irie K, Oishi I, Ueno N, et al. Identification of a member of the MAPKKK family as a potential mediator of TGF-beta signal transduction. Science. 1995; 270(5244):2008–11. PMID: 8533096.

55. Zhang YE. Non-Smad pathways in TGF-beta signaling. Cell Res. 2009; 19(1):128–39. https://doi.org/10.1038/cr.2008.328 PMID: 19114990; PubMed Central PMCID: PMC2635127.

56. Roberts PJ, Der CJ. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene. 2007; 26(22):3291–310. https://doi.org/10.1038/sj.onc.1210422 PMID: 17496923.

57. Scaltriti M, Baselga J. The epidermal growth factor receptor pathway: a model for targeted therapy. Clinical cancer research: an official journal of the American Association for Cancer Research. 2006; 12(18):5268–72. https://doi.org/10.1158/1078-0432.CCR-05-1554 PMID: 17000658.

58. Hong Z, Cabrera JA, Mahapatra S, Kutty S, Weir EK, Archer SL. Activation of the EGFR/p38/JNK pathway by mitochondrial-derived hydrogen peroxide contributes to oxygen-induced contraction of ductus arteriosus. Journal of molecular medicine. 2014; 92(9):995–1007. https://doi.org/10.1007/s00109-014-1162-1 PMID: 24906456; PubMed Central PMCID: PMC4134409.
59. Moustakas A, Heldin CH. Non-Smad TGF-beta signals. J Cell Sci. 2005; 118(Pt 16):3573–84. Epub 2005/08/18. https://doi.org/10.1242/jcs.02554 PMID: 16105881.

60. Yi JY, Shin I, Arteaga CL. Type I transforming growth factor beta receptor binds to and activates phosphatidylinositol 3-kinase. J Biol Chem. 2005; 280(11):10870–6. https://doi.org/10.1074/jbc.M413232300 PMID: 15657037.

61. Osman N, Getachew R, Burch M, Lancaster G, Wang R, Wang H, et al. TGF-beta stimulates biglycan core protein synthesis but not glycosaminoglycan chain elongation via Akt phosphorylation in vascular smooth muscle. Growth Factors. 2011; 29(5):203–10. Epub 2011/09/15. https://doi.org/10.3109/08977194.2011.615747 PMID: 21913799.

62. Guo X, Ramirez A, Waddell DS, Li Z, Liu X, Wang XF. Axin and GSK3- control Smad3 protein stability and modulate TGF- signaling. Genes Dev. 2008; 22(1):106–20. Epub 2008/01/04. https://doi.org/10.1101/gad.1590908 PMID: 19271672; PubMed Central PMCID: PMC2151009.

63. Mills CN, Nowsheen S, Bonner JA, Yang ES. Emerging roles of glycogen synthase kinase 3 in the treatment of brain tumors. Frontiers in molecular neuroscience. 2011; 4:47. https://doi.org/10.3389/fnscr.2011.00047 PMID: 2275880; PubMed Central PMCID: PMC3223722.

64. Vacca F, Bagnato A, Catt KJ, Tecce R. Transactivation of the epidermal growth factor receptor in endothelin-1-induced mitogenic signaling in human ovarian carcinoma cells. Cancer Res. 2000; 60(18):5310–7. Epub 2000/10/04. PMID: 11016663.

65. Rosano L, Di Castro V, Spinella F, Tortora G, Nicotra MR, Natali PG, et al. Combined targeting of endothelin A receptor and epidermal growth factor receptor in ovarian cancer shows enhanced antitumor activity. Cancer research. 2007; 67(13):6351–9. https://doi.org/10.1158/0008-5472.CAN-07-0883 PMID: 17616694.

66. Spinella F, Caprara V, Di Castro V, Rosano L, Cianfrocca R, Natali PG, et al. Endothelin-1 induces the transactivation of vascular endothelial growth factor receptor-3 and modulates cell migration and vasculogenic mimicry in melanoma cells. Journal of molecular medicine. 2013; 91(3):395–405. https://doi.org/10.1007/s00109-012-0956-2 PMID: 22965194.

67. Sun P, Xiong H, Kim TH, Zhang Z, Ren B. Beta-Catenin activates the growth factor endothelin-1 in colon cancer cells. Oncogene. 2005; 24(4):597–604. https://doi.org/10.1038/sj.ong.1202837 PMID: 15558022.

68. Kim TH, Xiong H, Zhang Z, Ren B. Beta-Catenin activates the growth factor endothelin-1 in colon cancer cells. Oncogene. 2005; 24(4):597–604. https://doi.org/10.1038/sj.ong.1202837 PMID: 15558022.

69. Blaschke F, Bruemmer D, Law RE. Egr-1 is a major vascular pathogenic transcription factor in atherosclerosis and restenosis. Reviews in endocrine & metabolic disorders. 2004; 5(3):249–54. https://doi.org/10.1007/s00109-004-0957-8 PMID: 15211096.

70. Zhu X, Ozturk F, Pandey S, Guda CB, Nawshad A. Implications of TGFbeta on Transcrip tome and Cellular Biofunctions of Palatal Mesenchyme. Frontiers in physiology. 2012; 3:85. https://doi.org/10.3389/fphys.2012.00085 PMID: 22514539; PubMed Central PMCID: PMC3325257.

71. Ghiselli G, Maccarana M. Drugs affecting glycosaminoglycan metabolism. Drug discovery today. 2011; 25(1):16–28. https://doi.org/10.1016/j.drudis.2011.04.001 PMID: 22971760.

72. Khachigian LM, Lindner V, Williams AJ, Collins T. Egr-1-induced endothe lial gene expression: a conserved mechanism in vascular injury. Science. 1996; 271(5254):1427–31. PMID: 8596917.

73. McCaffrey TA, Fu C, Du B, Eksinar S, Kent KC, Bush H Jr., et al. High-level expression of Egr-1 and Egr-1-inducible genes in mouse and human atherosclerosis. J Clin Invest. 2000; 105(5):653–62. https://doi.org/10.1172/JCI8592 PMID: 10712437; PubMed Central PMCID: PMC2897183.

74. Miller MK, Bang ML, Witt CC, Labeit D, Trombitas C, Watanabe K, et al. The muscle ankyrin repeat proteins: CARP, ankrd2/App and DARP as a family of titin filament-based stress response molecules. Journal of molecular biology. 2003; 333(5):333–9. https://doi.org/10.1016/S0022-2836(03)00011-6 PMID: 14670837.

75. Harja E, Bucciarelli LG, Lu Y, Stem DM, Zou YS, Schmidt AM, et al. Early growth response-1 promotes atherogenesis: mice deficient in early growth response-1 and apolipoprotein E display decreased atherosclerosis and vascular inflammation. Circ Res. 2004; 94(3):333–9. https://doi.org/10.1161/01.RES.0000112405.61577.95 PMID: 15211096.

76. Jeyaseelan R, Poizat C, Baker RK, Abdishoo S, Isterabadi LB, Lyons GE, et al. A novel cardiotoxic signal for doxorubicin. CARP, a nuclear modulator of gene expression in cardiac progenitor cells and cardiomyocytes. J Biol Chem. 1997; 272(36):22800–8. PMID: 9278441.

77. Kanai H, Tanaka T, Aihara Y, Takeda S, Kawabata M, Miyazono K, et al. Transforming growth factor-beta/Smad signaling induces transcription of the cell type-restricted ankyrin repeat protein CARP
gene through CAGA motif in vascular smooth muscle cells. Circ Res. 2001; 88(1):30–6. PMID: 11139470.

79. Labbe E, Lock L, Letamendia A, Gorska AE, Gryfe R, Gallinger S, et al. Transcriptional cooperation between the transforming growth-factor-beta and Wnt pathways in mammary and intestinal tumorigenesis. Cancer research. 2007; 67(1):75–84. https://doi.org/10.1158/0008-5472.CAN-06-2559 PMID: 17210685.

80. Ponsuksili S, Murani E, Phatsara C, Schwerin M, Schellander K, Wimmers K. Porcine muscle sensory attributes associate with major changes in gene networks involving CAPZB, ANKRD1, and CTBP2. Functional & integrative genomics. 2009; 9(4):455–71. https://doi.org/10.1007/s10142-009-0131-1 PMID: 19597856.

81. Zhong L, Chiusa M, Cadar AG, Lin A, Samaras S, Davidson JM, et al. Targeted inhibition of ANKRD1 disrupts sarcomeric ERK-GATA4 signal transduction and abrogates phenylephrine-induced cardiomyocyte hypertrophy. Cardiovascular research. 2015; 106(2):261–71. https://doi.org/10.1093/cvr/cvv108 PMID: 25770146; PubMed Central PMCID: PMC441572.

82. Burch ML, Yang SN, Ballinger ML, Getachew R, Osman N, Little PJ. TGF-β stimulates biglycan synthesis via p38 and ERK phosphorylation of the linker region of Smad2. Cell Mol Life Sci. 2010 67:2077–90. https://doi.org/10.1007/s00018-010-0315-9 PMID: 20213272.

83. Rostam MA, Kamato D, Piva TJ, Zhenge W, Little PJ, Osman N. The role of specific Smad linker region phosphorylation in TGF-β mediated expression of glycosaminoglycan synthesizing enzymes in vascular smooth muscle. Cellular Signalling. 2016. Epub 3 May 2016. https://doi.org/10.1016/j.cellsig.2016.05.002 PMID: 27153775

84. Bower JE, Ganz PA, Aziz N, Fahey JL. Fatigue and proinflammatory cytokine activity in breast cancer survivors. Psychosomatic medicine. 2002; 64(4):604–11. PMID: 12140350.

85. Chen H, Sampath P, Hou W, Thorne SH. Regulating cytokine function enhances safety and activity of genetic cancer therapies. Molecular therapy: the journal of the American Society of Gene Therapy. 2013; 21(1):167–74. https://doi.org/10.1038/mt.2012.225 PMID: 23261444; PubMed Central PMCID: PMC3538315.

86. Esquivel-Yelaquez M, Ostoa-Saloma P, Palacios-Arreola MI, Nava-Castro KE, Castro JJ, Morales-Montor J. The role of cytokines in breast cancer development and progression. Journal of interferon & cytokine research: the official journal of the International Society for Interferon and Cytokine Research. 2015; 35(1):1–16. https://doi.org/10.1089/jir.2014.0026 PMID: 25068787; PubMed Central PMCID: PMC4291218.

87. Normanno N, De Luca A, Bianco C, Strizzi L, Mancino M, Maiello MR, et al. Epidermal growth factor receptor (EGFR) signaling in cancer. Gene. 2006; 366(1):2–16. https://doi.org/10.1016/j.gene.2005.10.018 PMID: 16377102.

88. Normanno N, De Luca A, Maiello MR, Campiglio M, Napolitano M, Mancino M, et al. The MEK/MAPK pathway is involved in the resistance of breast cancer cells to the EGFR tyrosine kinase inhibitor gefitinib. J Cell Physiol. 2006; 207(2):420–7. https://doi.org/10.1002/jcp.20588 PMID: 16419029.

89. Pasche B, Pennison MJ, Jimenez H, Wang M. TGFB1R and cancer susceptibility. Transactions of the American Clinical and Climatological Association. 2014; 125:300–12. PMID: 25125747; PubMed Central PMCID: PMC4112675.
96. Principe DR, Doll JA, Bauer J, Jung B, Munshi HG, Bartholin L, et al. TGF-beta: duality of function between tumor prevention and carcinogenesis. Journal of the National Cancer Institute. 2014; 106(2): djt369. https://doi.org/10.1093/jnci/djt369 PMID: 24511106; PubMed Central PMCID: PMC3952197.

97. Moore-Smith L, Pasche B. TGFBR1 signaling and breast cancer. Journal of mammary gland biology and neoplasia. 2011; 16(2):89–95. https://doi.org/10.1007/s10911-011-9216-2 PMID: 21461994; PubMed Central PMCID: PMC4753062.

98. Kretzschmar M, Doody J, Timokhina I, Massague J. A mechanism of repression of TGFbeta/Smad signaling by oncogenic Ras. Genes Dev. 1999; 13(7):804–16. Epub 1999/04/10. PMID: 10197981; PubMed Central PMCID: PMC316599.

99. Matsuzaki K, Kitano C, Murata M, Sekimoto G, Yoshida K, Uemura Y, et al. Smad2 and Smad3 phosphorylated at both linker and COOH-terminal regions transmit malignant TGF-beta signal in later stages of human colorectal cancer. Cancer Res. 2009; 69(13):5321–30. Epub 2009/06/18. https://doi.org/10.1158/0008-5472.CAN-08-4203 PMID: 19531654.

100. Suzuki R, Fukui T, Kishimoto M, Miyamoto S, Takahashi Y, Takeo M, et al. Smad2/3 linker phosphorylation is a possible marker of cancer stem cells and correlates with carcinogenesis in a mouse model of colitis-associated colorectal cancer. Journal of Crohn’s & colitis. 2015; 9(7):565–74. https://doi.org/10.1093/ecco-jcc/jjv073 PMID: 25908723.